Value proposition

Human. Health. Hope.

H3 Biomedicine is a privately held biopharmaceutical company focused on the discovery and early development of novel, targeted anti-cancer compounds for the unmet needs of genetically defined patient populations.

H3 has leveraged its integrated expertise in genomics, tumor biology, bioinformatics and innovative synthetic organic chemistry to create an integrated drug development ecosystem to deliver patient-based, genomics-driven, small molecule drugs. In less than three years, H3 has developed four discovery platforms, which have produced two drug candidates for which the company expects to file investigational new drug (IND) applications in late 2015.

Founded by a $200 million dollar investment from Eisai Inc., and given operational and strategic independence, H3 has delivered on Eisai’s confidence with multiple platforms generating multiple lead programs. Having reached this inflection point, H3 is considering additional collaborators to fully realize the potential of its growing pipeline of lead programs and drug candidates.

H3 Biomedicine operates in the spirit of the collaboration and camaraderie encouraged by our corporate culture. Each team member has a unique role to play in the quest to develop new cancer drugs. H3 Biomedicine employees are dedicated and passionate individuals who recognize that our potential as a team is much greater than if any one of us was working alone.

Biopharmaceuticals, oncology treatment, cancer treatment, cancer research, human genetics, synthetic chemistry, cancer genomics, tumor biology, bioinformatics, and small molecule drugs